Mereo BioPharma (MREO) Gains from Investment Securities (2023 - 2026)
Mereo BioPharma (MREO) posted quarterly Gains from Investment Securities of -$17000.0 for Q1 2026, up 95.91% year-over-year from -$8677.3 in Q1 2025, and up 94.22% quarter-over-quarter from -$294000.0 in Q4 2025.
Mereo BioPharma (MREO) Gains from Investment Securities (2023 - 2026) Analysis & Trends
Mereo BioPharma (MREO) has reported Gains from Investment Securities for 4 consecutive years, with -$17000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Gains from Investment Securities rose 95.91% year-over-year to -$17000.0; the TTM figure through Mar 2026 stood at -$406000.0 (up 8.76% YoY), while the FY2025 annual figure was -$805000.0, down 292.12% from the prior year.
- Gains from Investment Securities rose to -$17000.0 in Q1 2026 per MREO's latest filing, from -$294000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $448000.0 in Q1 2024 and bottomed at -$542000.0 in Q1 2023.
- Historically, Gains from Investment Securities has averaged -$54000.0 across 4 years, with a median of $21000.0 in 2024.
- Annual changes were most pronounced in 2024 — Gains from Investment Securities soared 182.66% — and 2025, when it tumbled 432.2%.
- Mereo BioPharma's Gains from Investment Securities stood at $195000.0 in 2023, then tumbled by 180.51% to -$157000.0 in 2024, then plunged by 87.26% to -$294000.0 in 2025, then jumped by 94.22% to -$17000.0 in 2026.
- Business Quant data shows MREO's Gains from Investment Securities at -$17000.0 in Q1 2026, -$294000.0 in Q4 2025, and -$196000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Mereo BioPharma | 47.39 Mn | 47.39 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6,000.00 |
| Jun 30, 2026 | -6,000.00 |
| Mar 31, 2026 | -17,000.00 |
| Mar 31, 2026 | -17,000.00 |
| Dec 31, 2025 | -294,000.00 |
| Dec 31, 2025 | -294,000.00 |
| Sep 30, 2025 | -196,000.00 |
| Sep 30, 2025 | -196,000.00 |
| Jun 30, 2025 | 101,000.00 |
| Jun 30, 2025 | 101,000.00 |
| Mar 31, 2025 | -416,000.00 |
| Mar 31, 2025 | -416,000.00 |
| Dec 31, 2024 | -157,000.00 |
| Dec 31, 2024 | -157,000.00 |
| Sep 30, 2024 | 59,000.00 |
| Sep 30, 2024 | 59,000.00 |
| Jun 30, 2024 | 69,000.00 |
| Jun 30, 2024 | 69,000.00 |
| Mar 31, 2024 | 448,000.00 |
| Mar 31, 2024 | 448,000.00 |